Astrana Health, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 773.91M | 1.14B | 1.39B | 2.03B | 3.18B | 56.4% | |
| Cost of Revenue | (596.14M) | (944.68M) | (1.17B) | (1.76B) | (2.89B) | 63.7% | |
Gross Profit | 177.77M | 199.48M | 214.96M | 271.39M | 295.78M | 9.0% | |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | |
| Selling, General & Administrative | (62.08M) | (77.67M) | (112.60M) | (154.11M) | (217.26M) | 41.0% | |
| General & Administrative | (62.08M) | (77.67M) | (112.60M) | (154.11M) | (217.26M) | 41.0% | |
| Depreciation & Amortization | (17.52M) | (17.54M) | (17.75M) | (27.93M) | (45.75M) | 63.8% | |
Operating Income (EBIT) | 98.18M | 104.27M | 84.61M | 89.35M | 78.53M | -12.1% | |
| Non-Operating Items | |||||||
| Interest Income | 1.57M | 1.98M | 14.21M | 14.51M | 12.16M | -16.2% | |
| Interest Expense | (5.39M) | (7.92M) | (16.10M) | (33.10M) | (49.93M) | 50.9% | |
| Other Income/Expenses (Net) | -20.43M | -17.65M | 5.22M | -8.53M | -38.92M | 356.2% | |
Income Before Tax | 77.75M | 86.62M | 89.84M | 80.82M | 39.61M | -51.0% | |
| Income Tax Expense | (31.69M) | (40.88M) | (31.99M) | (30.89M) | (15.53M) | -49.7% | |
Net Income | 68.92M | 45.17M | 60.72M | 43.15M | 22.49M | -47.9% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $2 | $1 | $1 | $1 | $0 | -49.5% | |
| Weighted Avg Shares Outstanding | 43.83M | 44.97M | 46.71M | 47.69M | 49.08M | 2.9% | |
| Weighted Avg Shares Outstanding (Diluted) | 45.40M | 45.60M | 47.07M | 48.22M | 49.37M | 2.4% | |
EBITDA | 100.66M | 112.08M | 123.69M | 141.84M | 135.28M | -4.6% |
Explore ASTH
ASTH in the Healthcare
Small Cap